Conventional Nanosized Drug Delivery Systems for Cancer Applications

Cristian Vergallo Cristian Vergallo, Muhammad Nadeem Hafeez, Dalila Iannotta, Hélder A. Santos, Nicola d’Avanzo, Luciana Dini, Felisa Cilurzo, Massimo Fresta, Luisa Di Marzio, Christian Celia

Research output: Chapter in Book/Report/Conference proceedingChapterScientificpeer-review


Clinical responses and tolerability of conventional nanocarriers (NCs) are sometimes different from those expected in anticancer therapy. Thus, new smart drug delivery systems (DDSs) with stimuli-responsive properties and novel materials have been developed. Several clinical trials demonstrated that these DDSs have better clinical therapeutic efficacy in the treatment of many cancers than free drugs. Composition of DDSs and their surface properties increase the specific targeting of therapeutics versus cancer cells, without affecting healthy tissues, and thus limiting their toxicity versus unspecific tissues. Herein, an extensive revision of literature on NCs used as DDSs for cancer applications has been performed using the available bibliographic databases.
Original languageEnglish
Title of host publicationBio-Nanomedicine for Cancer Therapy
Number of pages25
Publication date2021
Publication statusPublished - 2021
MoE publication typeA3 Book chapter

Cite this